Ms. Elizabeth Barrett's most recent trade in Allogene Therapeutics Inc was a trade of 95,400 Restricted Stock Unit done . Disclosure was reported to the exchange on June 18, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Allogene Therapeutics Inc | Ms. Elizabeth Barrett | Director | 18 Jun 2026 | 95,400 | 95,400 | - | - | Restricted Stock Unit | ||
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | 31 Jan 2026 | 153,195 | 153,195 | - | - | Restricted Stock Units | ||
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | 28 Jul 2025 | 87,615 | 87,615 | - | - | Performance Stock Units | ||
| Allogene Therapeutics Inc | Ms. Elizabeth Barrett | Director | 18 Jun 2025 | 95,400 | 95,400 | - | - | Restricted Stock Unit | ||
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | 31 Jan 2025 | 96,377 | 96,377 | - | - | Restricted Stock Units | ||
| Allogene Therapeutics Inc | Ms. Elizabeth Barrett | Director | 05 Jun 2024 | 191,082 | 191,082 | - | - | Stock Option (Right to buy) | ||
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | 31 Jan 2024 | 87,615 | 87,615 | - | - | Restricted Stock Units | ||
| Allogene Therapeutics Inc | Ms. Elizabeth Barrett | Director | 13 Jun 2023 | 116,120 | 116,120 | - | - | Stock Option (Right to Buy) | ||
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | 31 Jan 2023 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | ||
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | 31 Jan 2023 | 100,000 | 100,000 | - | - | Performance Stock Units | ||
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | 31 Jan 2023 | 75,000 | 75,000 | - | - | Restricted Stock Units | ||
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | 31 Jan 2023 | 13,333 | 13,334 | - | - | Restricted Stock Units | ||
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 13,333 | 326,691 (1%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | 31 Jan 2023 | 5,000 | 0 | - | - | Restricted Stock Units | ||
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 5,000 | 313,358 (1%) | 0% | - | Ordinary Shares | |
| Allogene Therapeutics Inc | Ms. Elizabeth Barrett | Director | 15 Jun 2022 | 71,070 | 71,070 | - | - | Stock Option (Right to Buy) | ||
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | 31 Jan 2022 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | ||
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | 31 Jan 2022 | 13,333 | 26,667 | - | - | Restricted Stock Units | ||
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 13,333 | 314,318 (1%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.58 per share. | 31 Jan 2022 | 5,960 | 308,358 (1%) | 0% | 7.6 | 45,177 | Ordinary Shares |
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 5,000 | 303,220 (1%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | 31 Jan 2022 | 5,000 | 5,000 | - | - | Restricted Stock Units | ||
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.58 per share. | 31 Jan 2022 | 2,235 | 300,985 (1%) | 0% | 7.6 | 16,941 | Ordinary Shares |
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | 03 Jan 2022 | 105,689 | 0 | - | - | Restricted Stock Units | ||
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 105,689 | 345,188 (1%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Ms. Elizabeth Barrett | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 9.15 per share. | 03 Jan 2022 | 46,968 | 298,220 (1%) | 0% | 9.1 | 429,757 | Ordinary Shares |